Atezolizumab + Cabozantinib Postpones mCRPC Progression.

Published Date: 29 Jan 2024

Comparing combination to more hormonal therapy, PFS was improved, but the control arm was questioned.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

2.

Two medications might work better for breast cancers that are resistant to one.

3.

Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control

4.

Smarter targeted radiotherapy just as effective for low-risk breast cancer and reduces risk of side effects

5.

New research points out a promising strategy for treating metastatic medulloblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot